Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

530
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
530
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

469
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
469
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

816
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
816
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

197
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
197
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

908
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
908

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time electronic drug monitoring: experiences from a multinational phase 3 clinical trial to prevent multidrug-resistant TB.

IJTLD open·2026
Same author

Threshold cost of delivering preventive treatment for household contacts of people with multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Feasibility and acceptability of self-testing for COVID-19 in Ethiopia: a mixed-methods study.

IJTLD open·2025
Same author

Substance use during rifampicin-resistant TB treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Post-TB sequelae and care: a systematic review and synthesis of qualitative research.

IJTLD open·2025
Same author

Decision-makers' perspectives on the implementation of COVID-19 self-testing in Mozambique.

Public health action·2025

Related Experiment Video

Updated: Jan 11, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Optimising child-friendly TB preventive treatment regimens.

C Mulder1,2, A J Bergman3, F Mulatu4

  • 1Department of TB Elimination and Health System Innovations, KNCV Tuberculosis Foundation, The Hague, the Netherlands.

IJTLD Open
|November 17, 2025
PubMed
Summary
This summary is machine-generated.

The 3HP weekly regimen for tuberculosis preventive treatment (TPT) was preferred over daily 3RH by Ethiopian stakeholders due to lower dosing burden, though pill count remains a concern for improving child TPT adherence.

Keywords:
EthiopiaTBcaregiversisoniazidpaediatric TBrifampicinrifapentineshort-course regimens

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Related Experiment Videos

Last Updated: Jan 11, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pediatric Medicine

Background:

  • The World Health Organization (WHO) recommends rifamycin-based TB preventive treatment (TPT) for children.
  • Understanding factors influencing TPT regimen acceptability is crucial for effective implementation.
  • This study explored perceptions of two short-course TPT regimens in Ethiopia.

Purpose of the Study:

  • To assess the acceptability of two short-course TPT regimens (3HP and 3RH) among stakeholders in Ethiopia.
  • To identify factors influencing the choice between weekly (3HP) and daily (3RH) dosing for pediatric TPT.
  • To inform strategies for improving TPT adherence and outcomes in children.

Main Methods:

  • Conducted 47 in-depth interviews with caregivers, health workers, healthcare providers, and policymakers.
  • Utilized thematic content analysis to evaluate regimen acceptability.
  • Focused on factors including palatability, dosing frequency, pill burden, adherence, and side effects.

Main Results:

  • Both 3HP and 3RH regimens were generally well tolerated with mild side effects.
  • Weekly 3HP was perceived as less burdensome but posed adherence challenges (forgetting doses).
  • Daily 3RH presented a higher routine burden for caregivers; 3HP was preferred overall despite pill burden concerns.

Conclusions:

  • Stakeholders favored the 3HP regimen for its reduced dosing frequency.
  • Addressing pill burden and enhancing adherence support are key for successful pediatric TPT.
  • Child-friendly formulations and consideration of patient/caregiver preferences are vital for improving TPT outcomes.